Functional expression, inhibition and induction of CYP enzymes in HepaRG cells

Toxicology in Vitro

Volumn 23, Issue 4, 2009, Pages 748-753

  Turpeinen, Miia ^a,b   Tolonen, Ari ^b   Chesne, Christophe ^c   Guillouzo, André ^d   Uusitalo, Jouko ^b   Pelkonen, Olavi ^a  

^a UNIVERSITY OF OULU   (Finland)

^b Novamass Ltd   (Finland)

^c Biopredic International   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cell culture; Cytochrome P450; Drug metabolism; HepaRG; Hepatocyte; In vitro

Indexed keywords

AMFEBUTAMONE; AMODIAQUINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; ENZYME INHIBITOR; MELATONIN; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; TESTOSTERONE; TOLBUTAMIDE;

AGED; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; XENOBIOTIC METABOLISM;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL;

EID: 67349183384     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.03.008     Document Type: Article

References (25)

1. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouët S., Morel F., Guguen-Guillouzo C., and Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metabolism and Disposition 34 (2006) 75-83
2. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach S.R., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A., and Pharmaceutical Research Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. Drug Metabolism and Disposition 31 (2003) 815-832
3. Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., and Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45 (2007) 957-967
4. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidig A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., and Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Alternatives to laboratory animals: ATLA 34 (2006) 49-84
5. Cross D.M., and Bayliss M.K. A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metabolism Reviews 32 (2000) 219-240
6. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., and Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 15655-15660
7. Gomez-Lechon M.J., Donato M.T., Castell J.V., and Jover R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Current Drug Metabolism 5 (2004) 443-462
8. Guguen-Guillouzo C., Campion J.P., Brissot P., Glaise D., Launois B., Bourel M., and Guillouzo A. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biology International Reports 6 (1982) 625-628
9. Guillouzo A., Morel F., Fardel O., and Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 82 (1993) 209-219
10. Guillouzo A., and Guguen-Guillouzo C. Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opinion on Drug Metabolism & Toxicology 4 (2008) 1279-1294
11. Ioannides C., and Lewis D.F. Cytochromes P450 in the bioactivation of chemicals. Current Topics in Medicinal Chemistry 4 (2004) 1767-1788
12. Josse R., Aninat C., Glaise D., Dumont J., Fessard V., Morel F., Poul J.M., Guguen-Guillouzo C., and Guillouzo A. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metabolism and Disposition 36 (2008) 1111-1118
13. Kanebratt K.P., and Andersson T.B. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 36 (2008) 137-145
14. Kanebratt K.P., and Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metabolism and Disposition 36 (2008) 1444-1452
15. LeCluyse E.L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences 13 (2001) 343-368
16. Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton L.A., Krueger L.A., Downey A.D., Czerwinski M., Forster J., Ribadeneira M.D., Gan L.S., LeCluyse E.L., Zech K., Robertson Jr. P., Koch P., Antonian L., Wagner G., Yu L., and Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition 31 (2003) 421-431
17. Martinez-Jimenez C.P., Gomez-Lechon M.J., Castell J.V., and Jover R. Engineering human hepatoma cells with key transcription factors to generate metabolically competent hepatic models. ALTEX: Alternativen zu Tierexperimenten 23 (2006) 435-440
18. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., and Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology 82 (2008) 667-715
19. Tolonen A., Petsalo A., Turpeinen M., Uusitalo J., and Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. Journal of Mass Spectrometry 42 (2007) 960-966
20. Turpeinen M., Uusitalo J., Jalonen J., and Pelkonen O. Multiple 450 substrates in single run: rapid and comprehensive in vitro interaction assay. European Journal of Pharmaceutical Sciences 24 (2005) 123-132
21. Turpeinen M., Korhonen L.E., Tolonen A., Uusitalo J., Juvonen R., Raunio H., and Pelkonen O. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. European Journal of Pharmaceutical Sciences 29 (2006) 130-138
22. Turpeinen M., Raunio H., and Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Current Drug Metabolism 7 (2006) 705-714
23. Turpeinen M., Ghiciuc C., Opritoui M., Tursas L., Pelkonen O., and Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 37 (2007) 1367-1377
24. Walsky R.L., Obach R.S., Gaman E.A., Gleeson J.P., and Proctor W.R. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 33 (2005) 413-418
25. Zanger U.M., Turpeinen M., Klein K., and Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry 392 (2008) 1093-1108